However, HDAC inhibitors must be combined with conventional chemotherapy agents to demonstrate efficacy in extending survival in leukemic mice.12 This observation underscores the limitations of targeting HDAC alone and suggests the involvement of additional pathogenic factors and pathways in the pathogenesis of MEF2D fusion BCP-ALL. The gene discussed is HDAC9; the disease is acute lymphoblastic leukemia.